Trials / Completed
CompletedNCT01124318
A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults
Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Lactofiltrum, Orally Administered Tablets (Produced by AVVA RUS, JSC) to Treat Atopic Dermatitis in Adults
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Avva Rus, JSC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to study efficacy of Lactofiltrum in adult patients with atopic dermatitis. Lactofiltrum consists of 85% of hidrolytic lignin and 15% of lactulose and acts as an enterosorbent, which enables to enhance metabolism and elimination of endotoxins and to normalize metabolic and immune processes. Additionally, lactulose stimulates Bifidobacterium flora and in aggregate it could improve skin condition afflicted by atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lactofiltrum | Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days |
| DRUG | Placebo | Placebo 2 tablets 3 times a day before meals during 21 days |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2010-05-17
- Last updated
- 2010-09-14
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT01124318. Inclusion in this directory is not an endorsement.